Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom.

ABSTRACT: We report that in a cohort of 45,965 adults, who were receiving either the ChAdOx1 or the BNT162b2 SARS-CoV-2 vaccines, in those who had no prior infection with SARS-CoV-2, seroconversion rates and quantitative antibody levels after a single dose were lower in older individuals, especially in those aged >60 years. Two vaccine doses achieved high responses across all ages. Antibody levels increased more slowly and to lower levels with a single dose of ChAdOx1 compared with a single dose of BNT162b2, but waned following a single dose of BNT162b2 in older individuals. In descriptive latent class models, we identified four responder subgroups, including a 'low responder' group that more commonly consisted of people aged >75 years, males and individuals with long-term health conditions. Given o

SUBMITTER: Wei J 

PROVIDER: S-EPMC8294260 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature